Page 94 - Human Use News Today

 The Lancet Neurology publishes results from Minoryx Therapeutics Phase 2/3 ADVANCE clinical trial of leriglitazone in X-linked Adrenoleukodystrophy Leriglitazone was well tolerated, and significant benefit was shown through clinically meaningful myelopathy endpoints and reduced progression of cerebra...

/CNW/ - Health Canada has accepted a New Drug Submission (NDS) for nirsevimab, the first investigational single-dose long-acting antibody designed for all...

The Costa Rican Ministry of Health issued an executive decree to recognize in Costa Rica the marketing approval granted to pharmaceuticals by the…

ASTM has published the revision of ASTM E3263 "Standard Practice For Qualification Of Visual Inspection Of Pharmaceutical Manufacturing...

New administration option for first and only severe asthma biologic approved in the EU with no phenotype or biomarker limitations AstraZenecas Tezspire has received a positive opinion from the... | January 13, 2023

Tezspire approved for self-administration in the EU in a new pre-filled pen New administration option for first and only severe asthma biologic approved in the EU with no phenotype or biomarker limitations AstraZeneca’s Tezspire (tezepelumab) has received a positive opinion from the Europea...

Green light for new asthma pen which offers self-administration option across the EU - News - PharmaTimes

Tezspire is the first biologic approved in Europe for severe asthma with no phenotype or biomarker limitation, says AstraZeneca EVP.

BOSTON, Jan. 12, 2023 /PRNewswire/ -- Data Bridge Market Research has recently published a Report, titled, "G-CSFPEG-G-CSF Market" The report offers an

Eflornithine method for use patent from Michigan State University/Corewell Health® relates to treating patients with rare Bachmann-Bupp Syndrome...